Objective: To investigate the clinical significance of plasma p-amyloid 1-40 (Aβ1-40) in patients with Alzheimer's disease (AD).
Methods: In this retrospective study, the clinical data of 305 patients, with or without Alzheimer's disease (AD), who were treated at the Affiliated Hospital of Youjiang Medical University for Nationalities and the People's Hospital of Baise between January 2018 and December 2021 were analyzed. Patients were divided into two groups: an AD group (n=147) and a non-AD group (without AD, n=158 cases).